Research Summary

Hope S. Rugo, MD, FASCO, is professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she is also the director of Breast Oncology and Clinical Trials Education. Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California San Francisco in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer, and has published widely in this area. Her current research interests include immunotherapy and combinations of targeted agents in the treatment of breast cancer to overcome resistance. She was a member of the steering committee for the EMBRACA and ABRAZO studies that evaluated the efficacy of the PARP inhibitor talazoparib in patients with metastatic breast cancer and germline mutations in BRCA1 and 2. In addition, Dr. Rugo has conducted a number of studies focusing on reducing toxicity from therapy, resulting in approval of scalp cooling to reduce chemotherapy induced hair loss, and a steroid mouthwash to reduce targeted agent stomatitis. She is an investigator and the chair of the Safety Committee for the multicenter adaptively randomized phase II I-SPY2 trial, and serves on the Novel Agents Committee. Dr. Rugo is the co-chair of the Triple Negative Working Group and an active member of the Translational Breast Cancer Research Consortium (TBCRC), and is the principal investigator of several TBCRC trials including a multi-center immunotherapy trial funded by the Breast Cancer Research Foundation (BCRF). She is an active member of the Alliance (formerly CALGB) Breast Committee, as well as ASCO, where she serves on the Guidelines Committee and as an editor for the Education Committee.

In addition to her research, Dr. Rugo is an active clinician, and is committed to education, regularly lecturing locally, nationally and internationally on subjects relating to the treatment of and supportive care for breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she received an honor for her work in Breast Cancer Research by the Friends of the Breast Care Center and received the Cancer Care physician of the year award in 2010 by the Cancer Care National Organization.

Research Funding

  • December 1, 1974 - September 29, 2006 - General Clinical Research Center, Co-Investigator. Sponsor: NIH/NCRR, Sponsor Award ID: M01RR000079
  • December 1, 1974 - September 29, 2006 - General Clinical Research Center, Co-Investigator. Sponsor: NIH/NCRR, Sponsor Award ID: M01RR000079
  • December 1, 1974 - September 29, 2006 - General Clinical Research Center, Co-Investigator. Sponsor: NIH/NCRR, Sponsor Award ID: M01RR000079
  • December 1, 1974 - September 29, 2006 - General Clinical Research Center, Co-Investigator. Sponsor: NIH/NCRR, Sponsor Award ID: M01RR000079

Education

Tufts University, BS, 1979, Chemistry
University of Pennsylvania, MD, 1984, Medicine
University of California San Francisco, 1987, Resident, Internal Medicine
University of California San Francisco, 1990, Fellow, Hematology/Oncology
Stanford University, 1988-90, Postdoctoral Fellowship, Microbiology/Immunology
DNAX Institute of Cellular and Molecular Biology, 1989-90, Visiting Scientist, Immunology

Honors & Awards

  • College
    Summa Cum Laude, Phi Beta Kappa, Sigma Xi; Victor Prather Prize for Excellence in Scientific Research; Durkee Scholarship for promise and achievement in the field of chemistry; Max Tishler Prize Scholarship for outstanding achievement in the sciences
  • Medical School
    Henry Luce Scholar in the Philippines; Certificate of Commendation, Philadelphia Area Project on Occupational Safety and Health; National Health Service Corps Scholarship; Janet M. Glasgow Memorial Achievement Citation
  • 1990
    Awarded Bank of America Gianini Foundation Research Fellowship

Selected Publications

  1. Turner S, Chia S, Kanakamedala H, Hsu WC, Park J, Chandiwana D, Ridolfi A, Yu CL, Zarate JP, Rugo HS Effectiveness of Alpelisib + Fulvestrant Compared With Real-World Standard Treatment Among Patients With HR+, HER2-, PIK3CA-Mutated Breast Cancer.  View on PubMed
  2. Vidula N, Yau C, Rugo HS Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.  View on PubMed
  3. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, ASCENT Clinical Trial Investigators Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.  View on PubMed
  4. Ligibel JA, Huebner L, Rugo HS, Burstein HJ, Toppmeyer DL, Anders CK, Ma C, Barry WT, Suman V, Carey LA, Partridge AH, Hudis CA, Winer EP Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance).  View on PubMed
  5. Rugo HS, Huppert L Answers are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer.  View on PubMed
  6. Rugo HS, Huober J, Garcia-Saenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. In Reply to Badoui, et al.  View on PubMed
  7. Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.  View on PubMed
  8. Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, Herson J, Koch HF, Loganathan S, Deodhar S, Marwah A, Manikhas A, Bondarenko I, Parra JD, Abesamis-Tiambeng MLT, Akewanlop C, Vynnychenko I, Sriuranpong V, Roy S, Yanez Ruiz EP, Barve A, Waller CF Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.  View on PubMed
  9. Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.  View on PubMed
  10. Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.  View on PubMed
  11. DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.  View on PubMed
  12. Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley D, Karuturi MS, Sanft T, Blau S, Hart L, Ma CX, Rugo HS, Purkayastha D, Moulder-Thompson S Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1).  View on PubMed
  13. Cortesi L, Rugo HS, Jackisch C An Overview of PARP Inhibitors for the Treatment of Breast Cancer.  View on PubMed
  14. Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.  View on PubMed
  15. Dixit N, Rugo H, Burke NJ Navigating a Path to Equity in Cancer Care: The Role of Patient Navigation.  View on PubMed
  16. Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.  View on PubMed
  17. Rugo HS, Haltner A, Zhan L, Tran A, Bananis E, Hooper B, Mitra D, Cameron C Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.  View on PubMed
  18. Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.  View on PubMed
  19. Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+?and androgen receptor-positive metastatic or locally advanced breast cancer.  View on PubMed
  20. Jackisch C, Barcenas CH, Bartsch R, Palma JD, Glück S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HS Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.  View on PubMed

Go to UCSF Profiles, powered by CTSI